Latest News and Press Releases

Topline data from three late-stage pamrevlumab trials expected through 1H 2024, including the Pancreatic Cancer Action Network (PanCAN) Precision PromiseSM Phase 2/3 study in metastatic pancreatic...

BIRMINGHAM, Ala., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Harbert Management Corporation (“HMC”) announces the promotion of Claude Estes to Head of Infrastructure and Senior Managing Director. In his new...

SAN FRANCISCO, Feb. 04, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the SVB Leerink...

BIRMINGHAM, Ala., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Harbert Infrastructure is pleased to announce that it has hired Adam Nygaard as a Vice President, Investments. Mr. Nygaard joins Harbert...

SAN FRANCISCO, May 27, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following...

SAN FRANCISCO, May 08, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will participate in the Bank of America Securities 2020 Health Care Conference that is being held virtually on May...

SAN FRANCISCO, Nov. 04, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced that financial results for the third quarter 2019 will be released after market on Monday, November...

SAN FRANCISCO, Oct. 07, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) is pleased to announce that William G. Kaelin, Jr., who serves on the company’s Scientific Advisory Board, has been...

SAN FRANCISCO, Sept. 26, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced first patient dosed in the company’s Phase 2 clinical study of roxadustat, a first-in-class...

SAN FRANCISCO and TOKYO, Sept. 20, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq: FGEN, Interim CEO: James A. Schoeneck, “FibroGen”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji...